Tag: AI Drug Discovery
First AI-found brain target advances in Recursion-Roche pact
The first neuroscience target found through Recursion's $12B AI pact with Roche and Genentech is moving into an early discovery…
Novo Nordisk taps H1’s AI to speed trial design and site selection
Novo Nordisk partners with provider data company H1 to bring AI to trial design, enrollment and site selection.
GSK deepens AI drug discovery bet with $110M Relation expansion
GSK is paying AI biotech Relation up to $110M to generate human cell data and train foundation models for drug…
Raygun AI resizes natural proteins without losing their function
Duke University's Raygun AI can shrink or enlarge natural proteins without breaking their shape, opening new options for biologic drug…
Schrodinger launches Bunsen AI co-scientist for physics-powered drug discovery
Schrodinger launched Bunsen, an agentic AI co-scientist combining physics-based simulation with LLMs for drug discovery.
AI shrinks drug discovery timelines with data-driven biologics design
MIT Technology Review explores how AstraZeneca and others use AI to compress drug discovery and target previously untreatable diseases.
Bristol Myers Squibb partners with Nvidia on AI factory for drug discovery
BMS is building dedicated AI compute infrastructure with Nvidia to accelerate molecular modeling and drug discovery.
Belgian techbio startup Sightera raises $3.2M for AI-designed molecular glues
Belgian AI drug discovery startup Sightera Biosciences raises $3.2M to advance molecular glue therapies for hard-to-treat cancers and fibrosis.